Exact Sciences Balance Sheet Health
Financial Health criteria checks 3/6
Exact Sciences has a total shareholder equity of $2.5B and total debt of $2.3B, which brings its debt-to-equity ratio to 93%. Its total assets and total liabilities are $5.9B and $3.4B respectively.
Key information
92.97%
Debt to equity ratio
US$2.33b
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.00b |
| Equity | US$2.50b |
| Total liabilities | US$3.40b |
| Total assets | US$5.90b |
Recent financial health updates
Recent updates
Abbott To Complete $21B M&A Deal For Exact Sciences - What Investors Should Know
Nov 20Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 37% But Its Business Prospects Need A Lift Too
Nov 20
Exact Sciences Corporation's (NASDAQ:EXAS) Price Is Right But Growth Is Lacking After Shares Rocket 31%
Sep 08Exact Sciences Corporation (NASDAQ:EXAS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
May 07Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report
May 05
Cologuard Plus And Oncodetect Will Improve Cancer Screening Outcomes
Cologuard Plus and rescreening efforts are key drivers of revenue growth, bolstered by payer coverage and an increasing pool of eligible individuals.Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Mar 19Exact Sciences: Cost Optimization And Product Strength
Aug 18Exact Sciences: Still No Reason To Own
Jun 11Financial Position Analysis
Short Term Liabilities: EXAS's short term assets ($1.6B) exceed its short term liabilities ($584.3M).
Long Term Liabilities: EXAS's short term assets ($1.6B) do not cover its long term liabilities ($2.8B).
Debt to Equity History and Analysis
Debt Level: EXAS's net debt to equity ratio (52.9%) is considered high.
Reducing Debt: EXAS's debt to equity ratio has increased from 67.6% to 93% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable EXAS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: EXAS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 33.9% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/21 04:35 |
| End of Day Share Price | 2025/11/21 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exact Sciences Corporation is covered by 44 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Bruce Jackson | Benchmark Company |